During the past decade, Regional Institute of Ophthalmology conducted 3 clinical trials. In the 10-year time frame, 3 clinical trials started and 2 clinical trials were completed, i.e. on average, 66.7% percent of trials that started reached the finish line to date. In the past 5 years, 1 clinical trials started and 2 clinical trials were completed. i.e. 200% of trials that started reached the finish line.

According to Clinical.Site data, the most researched conditions in "Regional Institute of Ophthalmology" are "Adenoviral Conjunctivitis" (1 trials), "Intermediate Uveitis" (1 trials), "Neovascular Age-related Macular Degeneration" (1 trials), "Panuveitis" (1 trials) and "Posterior Uveitis" (1 trials). Many other conditions were trialed in "Regional Institute of Ophthalmology" in a lesser frequency.

Most popular intervention types in "Regional Institute of Ophthalmology" are "Drug" (3 trials) and "Other" (1 trials). Other intervention types were less common.

The name of intervention was led by "FAI Insert" (1 trials), "LUBT010 (proposed ranibizumab biosimilar)" (1 trials), "Lucentis (ranibizumab)" (1 trials), "PVP-I 0.6%" (1 trials) and "Placebo" (1 trials). Other intervention names were less common.

The vast majority of trials in "Regional Institute of Ophthalmology" are 3 trials for "All" genders.

Currently, there are NaN active trials in "Regional Institute of Ophthalmology". undefined are not yet recruiting, undefined are recruiting, undefined are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 1 completed trials in Regional Institute of Ophthalmology, undefined suspended trials, and 1 terminated clinical trials to date.

Out of the total trials that were conducted in Regional Institute of Ophthalmology, 0 "Phase 1" clinical trials were conducted, 0 "Phase 2" clinical trials and 3 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".